What does Kairos Pharma do?
Kairos Pharma, Ltd. is a Los Angeles-based clinical-stage biotechnology company listed on NYSE American under KAPA. It develops oncology therapies intended to reverse drug resistance and immune suppression in the tumor microenvironment. Kairos has never generated product revenue and has no approved medicine. Its present assets are patents, licenses, trial programs, scientific personnel, and the possibility of future approvals or partnerships.
What is the scientific focus?
The lead program, ENV-105, is an antibody directed at CD105, or endoglin. Kairos argues that CD105 signaling helps tumors sustain resistance. ENV-105 is therefore designed to restore sensitivity to established drugs. Current trials combine it with androgen-receptor therapy in metastatic castration-resistant prostate cancer and with osimertinib in EGFR-mutated non-small cell lung cancer. The company’s official investor overview describes this “resensitization” thesis as the center of the platform.
How should readers classify the business?
How does Kairos Pharma expect to make money?
Kairos does not yet make money from customers. Cash comes mainly from shares, pre-funded warrants, and an equity line. The contingent long-term model is to advance candidates and later earn product, licensing, collaboration, or transaction economics. Royalties, milestones, and sublicensing shares owed to licensors mean Kairos would retain less than gross future revenue.
Where could future revenue come from?
What is the present financing model?
In FY2025, financing activities provided $6.660 million, primarily from equity and pre-funded-warrant issuance. Operating activities used $3.441 million in the same year. The FY2025 Form 10-K therefore shows the essential economic loop: capital markets fund R&D and overhead while clinical assets remain unmonetized.
Which pipeline programs matter most?
The portfolio contains seven disclosed candidates, but development weight is uneven. ENV-105 is the lead clinical asset with two human oncology programs. KROS-201 is the next planned clinical program; KROS-101, KROS-102, KROS-301, KROS-401, and ENV-205 are earlier. Near-term value is therefore concentrated in a few milestones despite broad scientific optionality.
How concentrated is development value?
What has the newest clinical evidence shown?
On July 15, 2026, Kairos reported that 13 patients treated with ENV-105 plus osimertinib had no ENV-105-associated Grade 3 or higher toxicities and that side effects were manageable. This is an early safety update, not proof of efficacy. The company’s July 15, 2026 clinical update also reiterated company-reported median progression-free survival above 13 months in the prostate program.
What does Kairos Pharma’s latest reporting period show?
The quarter ended March 31, 2026 shows higher clinical spending and lower cash. Revenue remained zero. R&D increased with the Phase 2 prostate trial, while G&A remained the larger cost category. Operations consumed more than $1.0 million in three months before the May manufacturing commitment and later strategic announcements.
How did expenses change year over year?
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Revenue | $0 | $0 | No commercial or collaboration revenue was recognized. |
| R&D expense | $0.684M | $0.493M | Clinical work, particularly the prostate study, increased development spending. |
| G&A expense | $1.006M | $0.773M | Public-company and financing infrastructure remain expensive relative to the trial budget. |
| Net loss | $1.654M | $1.262M | The quarterly loss widened 31.1% year over year. |
| Operating cash use | $1.036M | $0.714M | Cash burn increased 45.1%, partly reflecting working-capital timing and higher activity. |
What does the expense mix imply?
Which turning points shaped Kairos Pharma?
Kairos assembled its portfolio through academic relationships, licenses, a share-exchange acquisition, and public-market financing. Those choices created scientific access and a capital-light footprint, but also royalty obligations, concentrated leadership, outsourced manufacturing, and repeated equity issuance.
-
2013Incorporated in California as NanoGB13, Inc. This establishes a long pre-commercial development history.
-
2016Changed its name to Kairos Pharma and adopted a broader oncology identity.
-
2021Acquired Enviro Therapeutics through a share exchange, bringing ENV-105 and CD105 rights into the group.
-
2023Converted to Delaware and opened ENV-105 Phase 1 lung and randomized Phase 2 prostate trials in September.
-
2024Completed its IPO and created the KAPA public listing, expanding access to equity financing.
-
2025Kairos assumed Enviro’s license and supply obligations through novation, and Enviro was dissolved. This simplified the structure while transferring related liabilities to Kairos.
-
2026Signed a binding term sheet for proposed CL-273 rights, reported initial ENV-105 lung safety data, and announced a Bayer collaboration to evaluate ENV-105 with XOFIGO.
What did the 2026 strategic additions change?
The proposed CL-273 transaction would add a reversible, wild-type-sparing pan-EGFR molecule for EGFR-mutant lung cancer. The March 2026 term sheet gives the seller shares equal to 16.5% of Kairos on a fully diluted basis at closing, plus a potential $15 million regulatory-submission milestone and a 2% U.S. net-sales royalty. The March 2, 2026 Form 8-K states that closing remained subject to diligence and definitive documents. CL-273 could broaden the platform, but would add dilution and contingent obligations.
What gives Kairos Pharma a differentiated oncology position?
Kairos differentiates through a mechanistic proposition: treat resistance itself and extend established therapies. Combination development may be more practical than displacing entrenched treatment pathways. The July 22, 2026 Bayer collaboration announcement illustrates this approach: ENV-105 is being evaluated as a way to enhance XOFIGO activity in prostate cancer rather than as a stand-alone replacement.
Where could a moat come from?
A durable moat would require enforceable rights, reproducible evidence that CD105 drives clinically relevant resistance, combination-compatible safety, and relationships that improve trials or partnering. Kairos reports patent lives extending into the late 2030s and 2040 for parts of the portfolio. The stronger advantage, however, would be a validated biomarker-and-combination playbook that competitors cannot easily replicate.
Who are the real competitors?
| Competitive force | How it pressures Kairos | Kairos response | Research implication |
|---|---|---|---|
| Large oncology companies | More capital, broader trial networks, deeper regulatory teams, and existing commercial channels | Position ENV-105 as complementary to established agents | Partnership can be an advantage, but also leaves Kairos with less negotiating leverage. |
| Alternative resistance mechanisms | EGFR, MET, antibody-drug conjugate, radiopharmaceutical, and immune approaches may address the same post-progression patients | Target CD105 as a cross-therapy resistance node | Kairos must show incremental benefit, not merely biological plausibility. |
| Existing standard care | Physicians may prefer familiar sequencing unless combination data are compelling | Extend, rather than replace, drugs such as osimertinib, apalutamide, or XOFIGO | Adoption depends on added efficacy, manageable toxicity, and reimbursement for the combination. |
| Capital competition | Hundreds of biotech programs compete for investor and partner funding | Use differentiated interim data and academic relationships to attract capital | Financing terms may determine which scientific programs survive long enough to mature. |
How financially strong is Kairos Pharma?
Kairos is liquid relative to current liabilities but not relative to development obligations. At March 31, 2026, current assets were $4.443 million, current liabilities were $0.431 million, and cash was $3.675 million. The balance-sheet classification does not mean the clinical plan is fully funded.
What does the cash trend show?
| Financial-health item | Official figure | Period | Analytical reading |
|---|---|---|---|
| Stockholders’ equity | $5.313M | March 31, 2026 | Positive accounting equity, but mostly the result of contributed capital. |
| Accumulated deficit | $15.916M | March 31, 2026 | Cumulative losses are expected for development-stage biotech, yet they quantify financing already consumed. |
| FY2025 operating cash use | $3.441M | Year ended December 31, 2025 | Operating burn is the key denominator for liquidity analysis. |
| Potentially dilutive securities | 5.054M | March 31, 2026 | Warrants and RSUs equal about 23.6% of the 21.411M basic shares then outstanding. |
How does capital allocation affect the story?
| Use or source of capital | Amount | Period / commitment | What it signals |
|---|---|---|---|
| R&D expense | $2.135M | FY2025 | Up 415.7% from FY2024 as clinical activity accelerated. |
| G&A expense | $3.437M | FY2025 | Corporate costs exceeded R&D by $1.302M. |
| Equity financing inflow | $6.660M | FY2025 financing cash flow | The balance sheet was replenished by shareholders rather than customers. |
| ENV-105 manufacturing commitment | $0.783M | Agreement signed May 11, 2026 | Clinical supply is a material claim on cash. |
Who owns Kairos Pharma stock, and why does it matter?
Kairos has one common-stock class with one vote per share, but influence is concentrated. The 2026 proxy reported Chief Executive Officer and Chairman John S. Yu with 5,347,170 beneficially owned shares, or 25.0% of the 21,411,198 shares used for the proxy calculation. Directors and executive officers as a group held 6,826,037 shares, or 31.9%. That alignment supports long-horizon decisions while concentrating agenda-setting influence.
What governance decisions change per-share interpretation?
| Governance fact | 2026 detail | Why it matters |
|---|---|---|
| Board structure | Four directors; three classified as independent | Formal independence exists, while the CEO also serves as chair and largest disclosed insider holder. |
| Reverse-split authorization | Approved range of 1-for-3 to 1-for-250, board-determined | Provides listing flexibility but does not change enterprise value; it can signal pressure on share-price compliance. |
| Equity-plan expansion | 5,000,000 additional shares plus a 5% annual evergreen for ten years | Supports hiring and retention while increasing potential dilution beyond existing warrants and RSUs. |
The ownership figures come from the 2026 definitive proxy statement. The later annual-meeting Form 8-K confirmed approval of the reverse-split authority and equity-plan amendments. For investors, the practical question is not simply “who owns KAPA?” but how insider concentration, compensation shares, warrants, acquisition consideration, and future financing combine to change ownership per share.
What opportunities and risks could change the story?
Kairos is highly event-sensitive. A few clinical, financing, or partnership developments can change risk-adjusted value sharply. The opportunity is repeatable restoration of sensitivity across therapies and tumors; the constraint is funding enough evidence before dilution becomes prohibitive.
Which opportunities deserve monitoring?
What risks are most material?
| Risk | Company-specific exposure | Financial line affected | What to watch |
|---|---|---|---|
| Clinical failure or ambiguity | Lead value is concentrated in ENV-105 and early datasets | Pipeline asset value; future R&D | Randomized efficacy, dose selection, enrollment quality, and durability. |
| Going-concern and dilution | $3.675M cash at March 31, 2026 versus ongoing quarterly burn and commitments | Cash, APIC, share count, loss per share | Financing size, price, warrants, ATM use, ELOC draws, and reverse-split implementation. |
| License dependence | Key assets rely on Cedars-Sinai and TRC105/CD105 agreements | Royalties, milestones, patent costs | Milestone compliance, patent prosecution, amendments, and termination rights. |
| Manufacturing and vendors | No owned manufacturing facilities; May 2026 supply commitment of $0.783M | Vendor advances, cash, trial timing | Batch release, cGMP quality, cost escalation, and schedule slippage. |
| Small organization | One full-time and three part-time employees at FY2025 year-end | G&A, execution capacity | Key-person dependence, outsourcing oversight, and ability to run multiple programs. |
Why does Kairos Pharma matter for valuation?
A standard DCF starts with revenue, margins, reinvestment, and free cash flow. Kairos has none of those commercial baselines, so a single-stage DCF creates false precision. Use a probability-adjusted milestone model: define the treatment setting, estimate patients and net price, apply development and commercialization probabilities, subtract trial, manufacturing, royalty, milestone, and launch costs, discount for time and risk, and divide by a financing-aware fully diluted share count.
Which KPIs matter most?
| KPI | How to calculate or observe it | Why it matters for Kairos |
|---|---|---|
| Cash runway | Cash divided by normalized forward operating and trial cash use | Determines whether Kairos reaches the next value-inflecting readout before another financing. |
| Clinical enrollment | Patients enrolled versus target and timeline | Slow enrollment raises cost, delays data, and increases dilution risk. |
| Safety severity | Grade 3+ treatment-related events, discontinuations, and dose-limiting toxicities | Combination value requires tolerability on top of existing standard therapy. |
| Efficacy durability | Response, clinical benefit, progression-free survival, and duration versus control | A resistance-reversal thesis must produce clinically meaningful added time, not only tumor shrinkage. |
| Fully diluted share count | Basic shares plus warrants, RSUs, equity-plan awards, acquisition shares, and expected financing | Enterprise value can rise while dilution weakens per-share value. |
What should a DCF or rNPV model stress-test?
The company’s June 2026 shareholder letter emphasizes acquisitions and plans for the balance of 2026. A valuation model should treat those plans as scenarios, not booked value. The useful output is a range across success, timing, retained economics, dilution, and launch assumptions.
What is the key takeaway from Kairos Pharma analysis?
Kairos is testing a potentially partner-friendly concept: restore established cancer therapies by targeting resistance rather than replacing standard treatment. ENV-105 has two active clinical settings, early company-reported safety and prostate-efficacy signals, and a new collaboration pathway with Bayer. These assets are meaningful, but they are not regulatory validation, randomized proof, or revenue.
The company’s weakest point is financial endurance. Q1 2026 ended with $3.675 million of cash, no revenue, a $1.654 million quarterly net loss, and a going-concern warning. Warrants, RSUs, a larger equity plan, CL-273 consideration, and future raises make dilution central. Science can progress while each share’s claim changes materially.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.